01.05.2023 | Tracker

Top 50 Pharma Tracker: eHCPs applaud pharma collaborating with one another

By Imma Tinat

Discover what healthcare professionals (HCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are HCPs responding to drug launch news? How are HCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of HCPs across the globe discussing these topics and more.

The Top 50 Pharmaceutical Companies mentioned by HCPs on Twitter

April RankMarch RankCompany
Name
Total
Mentions
Account
Mentions
Account
Retweets
11Pfizer4,42749819
22Moderna2,129951
35AstraZeneca98530129
44Johnson & Johnson65817315
511Abbott47647011
67GSK39612431
716Merck & Co3141212
813Bayer2757912
99Roche26211345
1015Gilead Sciences2471011
1112Novartis2311615
128Sanofi21813437
133Lilly2021250
146Novo Nordisk1801234
1510AbbVie1591134
1617Biogen1581005
1714Takeda1201100
1824Otsuka107590
1918Eisai107850
2020Amgen85625
2122BMS74641
2221Boehringer Ingelheim63360
2326Astellas62500
2423Fresenius56214
2519Daiichi Sankyo53186
2625Stada4500
2735Servier423818
2828Vertex34330
2939Merck KGaA33239
3031Regeneron30193
3141Menarini282319
3230UCB20138
3336Bausch1940
3427Viatris1820
3532Organon1400
3634Jazz Pharmaceuticals1300
3729Teva972
3840Grifols810
3933Ipsen750
4038CSL770
4142Sun640
4242CSPC300
4237Alexion330
4444Kyowa Kirin200
4545Jiangsu Hengrui100
5050Aurobindo100
5050Endo000
5050Sino000
5050Shanghai000
5050Sumitomo Dainippon000

The latest insights from HCPs mentioning the Top 50 Pharmaceutical Companies

The five pharmaceutical companies that were mentioned the most by eHCPs on Twitter in April 2023 were Pfizer, Moderna, AstraZeneca, Johnson & Johnson and Abbott.

CREATION.co identified 10,580 eHCP mentions of pharmaceutical companies online in April 2023, decreasing by 17% from the previous month.

A chemist shared the news that Moderna and MSD’s collaborative vaccine against melanoma has been designated as a breakthrough therapy by the FDA. This garnered retweets from over 90 eHCPs on Twitter.

Roche and Eli Lilly received positive remarks from eHCPs on their collaboration for the early detection of Alzheimer’s. This gathered a lot of conversations around the disease with eHCPs sharing posts either creating awareness or simply discussing other treatment options for Alzheimer’s.

eHCPs discussed the benefits of tirzepatide, the “next-generation obesity drug” by Eli Lilly and shared results of the data from the SURMOUNT-2 study, showing efficacy.

The top shared links by HCPs when mentioning a Top 50 pharma company discussed:

  1. YouTube video by an online news show discussing Bristol Myers Squibb’s product, Abilify.
  2. An online news article sharing information about a protest held against Gilead.
  3. An online newspaper about Fresenius promising two million to a former deputy if he obtained contracts from a hospital.

In April, eHCPs reacted positively to pharmaceutical companies coming together to collaborate and work towards a goal in providing treatments to different therapy areas.

CREATION.co continues to analyse online HCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology notes:

    • In April 2023, CREATION Pinpoint® identified 10,580  healthcare professional authored tweets from 4,419 individual HCPs mentioning a Top 50 Pharmaceutical company (according to revenue). 
    • Data for this research was analysed from the online Twitter conversations of HCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 April and 30  April 2023.
  • Unless otherwise specified, mentions of a company are not limited to its Twitter account(s).
  • In some cases, a tweet may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
  • Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Janssen. In April 2023, 211 of these posts mentioned Janssen.

The Top 50 Pharma tracker archive

March 2022: eHCPs celebrate Eli Lilly for capping the cost of insulin

Top 50 Table 

Top 50 Insights

December 2022: HCPs celebrate the Moderna and Merck combination melanoma vaccine and immunotherapy

Top 50 Table 

Top 50 Insights

November 2022: HCPs actively discussed issues concerning mRNA and bivalent COVID-19 vaccines

Top 50 Table 

Top 50 Insights

October 2022: HCPs actively discussed issues concerning mRNA and bivalent COVID-19 vaccines

Top 50 Table

Top 50 Insights

September 2022: Top 50 Pharma Tracker: Bivalent vaccine data and new treatments drive HCP conversation

Top 50 Table

Top 50 Insights

August 2022: Top 50 Pharma Tracker: HCPs discuss bivalent vaccine approval in the UK and advances in obesity treatment.

Top 50 Table
Top 50 Insights

July 2022: Top 50 Pharma Tracker: HCPs continue to discuss Moderna’s COVID-19 vaccine but mentions of Pfizer dramatically decrease

Top 50 Table
Top 50 Insights

June 2022: Top 50 Pharma Tracker: HCPs share mixed opinions on COVID-19 vaccines and treatment data

Top 50 Table
Top 50 Insights

May 2022: Top 50 Pharma Tracker: HCPs discuss Pfizer vaccine documents and share opinions on COVID-19 vaccine efficacy.

Top 50 Table
Top 50 Insights

April 2022: HCPs celebrate the success of Lilly’s tirzepatide for obesity and discuss COVID-19 vaccine efficacy

Top 50 Table
Top 50 Insights

March 2022: HCPs compare immune responses of T cell, B cell, and Antibodies to different COVID-19 vaccines.

Top 50 Table
Top 50 Insights

February 2022: HCPs discuss Healthcare inequity and vaccination of under 5 year olds

Top 50 Table
Top 50 Insights

January 2022: HCPs get political when discussing Regeneron’s COVID-19 treatment

Top 50 Table
Top 50 Insights

December 2021: Omicron variant dominates HCP conversation in December 2021

Top 50 Table
Top 50 Insights

November 2021 : HCPs discuss trial data of Pfizer’s COVID-19 booster vaccine and oral treatment

Top 50 Table
Top 50 Insights

October 2021 : Pfizer most discussed company with booster and children’s COVID-19 jabs

Top 50 Table
Top 50 Insights

July 2021: HCPs discuss “booster shot” to decrease the high spread of the Delta variant

Top 50 Table
Top 50 Insights

June 2021: HCPs discuss effectiveness of COVID-19 vaccines against delta strain.

Top 50 Table
Top 50 Insights

May 2021: HCPs discuss accessibility of COVID-19 treatments globally.

Top 50 Table
Top 50 Insights

April 2021: HCPs reassure the public as they discuss COVID-19 vaccine side effects.

Top 50 Table
Top 50 Insights

March 2021: Oxford-AstraZeneca vaccine provokes HCP conversation as they discuss blood clots as a side effect.

Top 50 Table
Top 50 Insights

February 2021: J&J FDA approval of single-dose vaccine stirs HCP conversations

Top 50 Table
Top 50 Insights

January 2021: J&J new vaccine data drives increase in company posts online

Top 50 Table
Top 50 Insights

December 2020: COVID-19 makes up 84% of total conversation

Top 50 Table
Top 50 Insights

November 2020: Vaccine success dwarfs all other conversation.

Top 50 Table
Top 50 Insights

October 2020: Regeneron tops list due to high profile COVID-19 treatment conversation.

Top 50 Table
Top 50 Insights

September 2020: ASTRAZENECA’S VACCINE TRIAL SAFETY DISCUSSED BUT TRANSPARENCY IS CELEBRATED.

Top 50 Table
Top 50 Insights

August 2020: HCPS DISCUSS ASTRAZENECA MORE THAN GILEAD FOR FIRST TIME SINCE PANDEMIC

Top 50 Table
Top 50 Insights

July 2020: COVID-19 CANDIDATES TAKE OVER ALL HCP CONVERSATION

Top 50 Table
Top 50 Insights

June 2020: HCPs respond to COVID-19 treatment options

Top 50 Table
Top 50 Insights

May 2020: HCPs track pharma covid-19 developments online

Top 50 Table
Top 50 Insights

April 2020: HCPS RESPOND TO PHARMA COVID-19 ACTIVITY

Top 50 Table
Top 50 Insights

March 2020: HCPS MENTIONING PHARMA IN RELATION TO COVID-19

Top 50 Table
Top 50 Insights

February 2020: HCPS DISCUSS GILEAD, EISAI AND MERCK & CO’S TRIAL RESULTS

Top 50 Table
Top 50 Insights

January 2020: NEW YEAR BEGINS WITH FAILED TRIALS AND SUCCESSFUL PODCAST LAUNCH

Top 50 Table
Top 50 Insights

December 2019: @NOVARTIS MOST MENTIONED TWITTER ACCOUNT FOR SECOND MONTH

Top 50 Table
Top 50 Insights

November 2019: GILEAD INTO TOP 5 AFTER PRICE DISCREPANCY

Top 50 Table
Top 50 Insights

October 2019: HCPS ENGAGE WITH TOP 50 PHARMA AROUND GOOD AND BAD NEWS

Top 50 Table
Top 50 Insights

September 2019: HCPS ENGAGED MEANINGFULLY WITH TOP 50 PHARMA

Top 50 Table
Top 50 Insights

August 2019: #WHATHCPSTHINK ABOUT THE TOP 50 PHARMA

Top 50 Table
Top 50 Insights

View all articles >

Meet the Author

Imma Tinat

Imma is passionate to make an impact in the health industry and with her background in Artificial intelligence, she is very meticulous with providing insights for clients through data analysis.

Imma is very family oriented and enjoys spending time and making beautiful memories with family and friends - especially if it involves engaging them in a game of charades.

Suggested next


PM Society Digital Award Winner 2021: CREATION.co

17.09.2021 | Press Release

CREATION.co win Gold with Frontline.Live at 2021 PM Society Awards

CREATION.co win Gold with Frontline.Live at 2021 PM Society Awards

Our enemy is fear, not #coronavirus

12.02.2020 | Article

Our enemy is fear, not #coronavirus

Our enemy is fear, not #coronavirus

By Daniel Ghinn

View all articles >